COVID-19 mRNA vaccine plus immune system enhancer may reduce need for repeated boosters, say researchers

In a new study published in Nature Immunology, researchers at Boston Children's Hospital demonstrated that pairing the ...
The Scientist

Slowed But Not Stalled: The Future of mRNA Vaccine Research

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales

By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its ...

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...
Morningstar

Moderna's work developing seasonal vaccines is 'risky' under current FDA, analyst says

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.